Abstract
The key to the successful development of nuclear medicine therapy ward is the good management and organization. Nuclear medicine remains a highly technical field that not only uses advanced instrumentation but also implies many numerical techniques and data analysis. The direct use of unsealed sources of radiation for therapy demands attention to radiation safety for both family members and patients caregivers, as well as general public and environment. Radionuclides must be used in strict accordance with safety regulations and special instructions, and precautions must be taken in order to avoid unnecessary exposure to radiation. This chapter summarizes the steps to be taken before commencing therapy procedures and the prerequisites to establish a well-organized protocol by taking care for each step so as to achieve the full potential of the workforce for the benefit of the organization and the patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35(10):1827–37.
Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):293–309.
IAEA. Nuclear medicine resources manual. 2006.
IAEA-TECDOCs 649.
IAEA-TECDOCs 805.
European Directive 2011/70 EURATOM, 19-7-2011.
European Directive 2013/59 EURATOM, 5-12-2013.
ICRP publication 103 (The 2007 recommendations of the international commission on radiological protection).
ICRP 2011 annual report.
IAEA, Safety report series No 63 “Release of patients after radionuclide therapy”.
European Commission. Radiation protection following iodine-131 therapy (exposures due to out-patients or discharged in-patients), radiation protection 97. Luxembourg: European Commission; 1998.
Nuclear Regulatory Commission. Release of patients administered radioactive materials, regulatory guide no. 8.39. Washington, DC: US Govt Printing Office; 1997.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix
Appendix
IAEA: Examples of information/leaflet in Safety Reports Series No. 63
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Paphiti, M.I. (2021). Regulations and Requirements of Scientific Centers Performing Radiopeptide Therapies. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-70773-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70772-9
Online ISBN: 978-3-030-70773-6
eBook Packages: MedicineMedicine (R0)